NCT06399835View on ClinicalTrials.gov

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Type 2 Diabetes
Interventions
DRUG

Enavogliflozin

Enavogliflozin 0.3mg once daily

DRUG

Pioglitazone

Pioglitazone 15mg once daily

Trial Locations (1)

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

Sponsors
All Listed Sponsors
collaborator

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

lead

Seoul National University Bundang Hospital

OTHER

NCT06399835 - Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis | Biotech Hunter | Biotech Hunter